Line 65: | Line 65: | ||
letter-spacing: 1px; | letter-spacing: 1px; | ||
opacity: 0.9; | opacity: 0.9; | ||
+ | } | ||
+ | |||
+ | #please h5 { | ||
+ | font-family: Quicksand, sans-serif; | ||
+ | margin: 0 0 5px; | ||
+ | font-size: 0.9em; | ||
+ | letter-spacing: 1px; | ||
+ | opacity: 0.9; | ||
+ | color: #fff; | ||
} | } | ||
Line 312: | Line 321: | ||
<figcaption> | <figcaption> | ||
<h3>Stability</h3> | <h3>Stability</h3> | ||
− | < | + | <h5>For our project to work effectively, we must have a supply chain that’s not a cold chain, so that costs can be reduced. This will ultimately mean that the cost of these cold chains will not be passed onto the consumer. To achieve this, we hope to design an insulin that will not lose efficacy after being exposed to room temperature for long periods of time. |
− | </ | + | </h5> |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
Line 321: | Line 330: | ||
<figcaption> | <figcaption> | ||
<h3>Single Chained</h3> | <h3>Single Chained</h3> | ||
− | < | + | <h5>As a result of the difficult purification methods, Single Chain Insulins, or SCIs for short, have been developed with a small, C-peptide chain linker. This linker connects the A and B chains in such a way that the di-sulfide bonds form more favorably. We aim to develop our own single chain insulin to compare it’s simplicity. |
− | </ | + | </h5> |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
Line 330: | Line 339: | ||
<figcaption> | <figcaption> | ||
<h3>Ease of Purification and Affordaility</h3> | <h3>Ease of Purification and Affordaility</h3> | ||
− | < | + | <h5>We must also consider the impact of a difficult, costly manufacturing process on small scale manufacturing companies. This impact is too great to impose on this grass-roots organisations, so we have pursued to find a cheap, simple purification method which is able to produce high yields from a recombinant system. |
− | </ | + | </h5> |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
Line 339: | Line 348: | ||
<figcaption> | <figcaption> | ||
<h3>Intellectual Property Issues</h3> | <h3>Intellectual Property Issues</h3> | ||
− | < | + | <h5>As a result of the way drugs are currently developed, all new inventions for therapies are protected by Intellectual Property Law through patents. These patents surrounding all currently prescribed and newly invented insulins has inspired our team to pursue a completely open source project. |
− | </ | + | </h5> |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
Line 348: | Line 357: | ||
<figcaption> | <figcaption> | ||
<h3>Safety and Efficacy</h3> | <h3>Safety and Efficacy</h3> | ||
− | < | + | <h5>Our insulin products must be of certifiable medical grade such that it can be approved for human use after stage IV clinical trials, or biosimilar clinical trials. Furthermore, it must also be as effective at least, as the other insulins on the market. |
− | </ | + | </h5> |
</figcaption> | </figcaption> | ||
</figure> | </figure> |
Revision as of 04:52, 15 October 2017
Our Key Goals
The aim of the USYD iGEM 2017 team was to address the problem of insulin inaccessibility. The design of our insulin, and its means of expression, needed to look at five key characteristics: